Mary Z. Luo - Jan 8, 2024 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Signature
/s/ Eva Wen, by power of attorney for Mary Z. Luo
Stock symbol
AMPH
Transactions as of
Jan 8, 2024
Transactions value $
-$12,798,708
Form type
4
Date filed
1/10/2024, 06:27 PM
Next filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Sale -$1.07M -18.9K -1.3% $56.98 1.44M Jan 8, 2024 Direct F1, F2
transaction AMPH Common Stock Sale -$2.4M -41.3K -2.87% $58.25 1.4M Jan 8, 2024 Direct F1, F3
transaction AMPH Common Stock Sale -$2.24M -37.9K -2.71% $59.24 1.36M Jan 8, 2024 Direct F1, F4
transaction AMPH Common Stock Sale -$1.65M -27.6K -2.03% $59.99 1.33M Jan 8, 2024 Direct F1, F5
transaction AMPH Common Stock Sale -$261K -4.26K -0.32% $61.19 1.33M Jan 8, 2024 Direct F1, F6
transaction AMPH Common Stock Sale -$103K -1.66K -0.13% $61.81 1.32M Jan 8, 2024 Direct F1, F7
transaction AMPH Common Stock Sale -$136K -2.15K -0.16% $63.27 1.32M Jan 8, 2024 Direct F1, F8
transaction AMPH Common Stock Sale -$2.87M -50.7K -3.83% $56.70 1.27M Jan 9, 2024 Direct F1, F9
transaction AMPH Common Stock Sale -$1.83M -31.8K -2.5% $57.70 1.24M Jan 9, 2024 Direct F1, F10
transaction AMPH Common Stock Sale -$217K -3.71K -0.3% $58.35 1.24M Jan 9, 2024 Direct F1, F11
holding AMPH Common Stock 2.08M Jan 8, 2024 See footnote F12
holding AMPH Common Stock 6.83M Jan 8, 2024 See footnote F13
holding AMPH Common Stock 5K Jan 8, 2024 See footnote F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.57 to $57.555, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.60 to $58.59, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.61 to $59.60, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.61 to $60.595, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.625 to $61.595, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.65 to $62.42, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.08 to $63.395, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.15 to $57.14, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.15 to $58.14, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.15 to $58.64, inclusive.
F12 The securities are held of record by Jack Y. Zhang. The reporting persons are husband and wife.
F13 The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
F14 The shares are held of record by the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.